Guidance, NICE advice and quality standards in development | Guidance

Showing 141 to 150 of 401

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Familial Breast Cancer: initial assessment and genetic testing (update)	NICE guideline	22 April 2027
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]	Technology appraisal guidance	TBC
Fertility problems: assessment and treatment - update 1 and 2	NICE guideline	19 March 2026
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]	Technology appraisal guidance	TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]	Technology appraisal guidance	TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]	Technology appraisal guidance	4 June 2026
Flow tDCS	Medtech innovation briefings	TBC
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance	TBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]	Technology appraisal guidance	TBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]	Technology appraisal guidance	8 October 2025